In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including:

Rationale for targeting CELMoDs in NHL
Mechanism of action of CELMoDs
Key studies and available efficacy and safety data with investigational CELMoDs in NHL
Key ongoing clinical trials of CELMoDs in NHL
Strategies to boost NHL clinical trial diversity among underserved communities

Presenters:

Julio C. Chavez, MD, MS
Associate Member
Department of Malignant Hematology
ICE-T Clinical Research Medical Director for Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor
University of South Florida
Tampa, Florida

Alan Skarbnik, MD
Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North Carolina

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb.

Link to full program:
https://bit.ly/45YXoZI

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways